Secondary prevention medication use in patients with cardiovascular disease in Northwest China from 2015—2019
ZHONG Hui YU Yanwu HE Wei WANG Yunfeng ZHU Zhihong ZHANG Lihua LI Xi LIU Jiamin
National Clinical Research Center for Cardiovascular Diseases NHC Key Laboratory of Clinical Research for Cardiovascular Medications State Key Laboratory of Cardiovascular Disease Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College National Center for Cardiovascular Diseases, Beijing 100037, China
Abstract：Objective To investigate the secondary prevention drug use in patients with cardiovascular disease in the community population in Northwest China, and to explore its correlation with individual characteristics. Methods The participants aged 35-75 years from 43 communities in Northwest China were studied based on the “China Patient-Centered Evaluative Assessment of Cardiac Events Million Persons Project” from 2015—2019. The self-reported history of ischemic heart disease or ischemic stroke and drug use were collected through questionnaires. Associations between individual characteristics and secondary prevention medication use were analyzed using multivariate mixed-effects models. Results Among 14 212 patients with ischemic heart disease and / or ischemic stroke, 22.6% reported the use of antiplatelet or statin drugs. The results of multivariate analysis showed that older age (55 to 65 and 65 to 75 years old), middle school and above, married, overweight or obese, and those with hypertension were more likely to use antiplatelet or statin drugs (P ＜ 0.05); while women, farmers, rural areas, and smokers were less likely to take antiplatelet or statin drugs (P ＜ 0.05). Conclusion In patients with ischemic heart disease and/or ischemic stroke in Northwest China, the application of antiplatelet drugs and statins is insufficient, and the status also varies across different population characteristics.
钟慧 于炎武 何炜 王云锋 朱志鸿 张丽华 李希 刘佳敏. 2015—2019年我国西北地区心血管疾病患者人群二级预防用药情况[J]. 中国医药导报, 2022, 19(15): 57-60.
ZHONG Hui YU Yanwu HE Wei WANG Yunfeng ZHU Zhihong ZHANG Lihua LI Xi LIU Jiamin. Secondary prevention medication use in patients with cardiovascular disease in Northwest China from 2015—2019. 中国医药导报, 2022, 19(15): 57-60.
[1] 《中国脑卒中防治报告》编写组.《中国脑卒中防治报告2019》概要[J].中国脑血管病杂志，2020，17（5）：272-281.
[2] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志，2020，35（9）：833-854.
[3] 周脉耕，梁晓峰.降低疾病负担，促进全民健康[J].中国循环杂志，2018，33（12）：1145-1146.
[4] Trialists A. Aspirin in the primary and secondary prevention of vascular disease：collaborative meta-analysis of individual participant data from randomised trials [J]. Lancet，2009，373（9678）：1849-1860.
[5] Fuster V，Sweeny JM. Aspirin：A Historical and Contemporary Therapeutic Overview [J]. Circulation，2011，123（7）：768-778.
[6] Thomas H，Diamond J，Vieco A，et al. Global Atlas of Cardiovascular Disease 2000-2016：The Path to Prevention and Control [J]. Glob Heart，2018，13（3）：143-163.
[7] Fihn SD，Gardin JM，Abrams J，et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart diseass [J]. J Am Coll Cardiol，2012，60（24）：e44-e164.
[8] Montalescot G，Sechtem U，Achenbach S，et al. 2013 ESC guidelines on the management of stable coronary artery disease：the Task Force on the management of stable coronary artery disease of the European Society of Cardiology [J]. Eur Heart J，2013，34（38）：2949-3003.
[9] 吴晓燕，杨莉.我国主要心血管病死亡公平性分析[J].中国卫生事业管理，2020，37（12）：953-957.
[10] 姜莹莹，毛凡，张岩，等.我国各省心血管疾病相关健康资源分布评价[J].疾病监测，2020，35（5）：387-393.
[11] 张斌，张岩，赵冬，等.我国分省心血管病救治的现况评价——中国心血管健康指数解析[J].疾病监测，2020， 35（5）：401-405.
[12] 吴超群，李希，路甲鹏，等.中国居民心血管疾病危险因素分布报告[J].中国循环杂志，2021，36（1）：4-13.
[13] 王旭，李毅，李晶，等.比较不同地域ACS患者PCI术后的二级预防依从性和长期预后[J].中华心血管病杂志，2021，49（2）：143-149.
[14] Lu JP，Xuan S，Downing NS，et al. Protocol for the China PEACE （Patient-centered Evaluative Assessment of Cardiac Events） Million Persons Project pilot [J]. BMJ open，2016，6（1）：e010200.
[15] 高血压联盟，中国医疗保健国际交流促进会高血压分会，中国高血压防治指南修订委员会，等.中国高血压防治指南（2018年修订版）[J].中国心血管杂志，2019， 24（1）：25-56.
[16] Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults [J]. Biomed Environ Sci，2002，15（1）：83-96.
[17] Pearson ES，Clopper CJ. The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial [J]. Biometrika，1934，26（4）：404-413.
[18] Lu J，Zhang L，Lu Y，et al. Secondary prevention of cardiovascular disease in China [J]. Heart，2020，106（17）：1349-1356.
[19] 袁祖贻.不忘初心，方得始终：大数据分析西北地区慢性病防控[J].临床心血管病杂志，2018，34（8）：739-742.
[20] 庞元捷，余灿清，郭彧，等.中国成年人行为生活方式与主要慢性病的关联——来自中国慢性病前瞻性研究的证据[J].中华流行病学杂志，2021，42（3）：369-375.
[21] Nobre M，Domingues R. Patient adherence to ischemic heart disease treatment [J]. Revista Da Associacao Medica Brasileira，2017，63（3）：252-260.
[22] Jiang Y，Yang X，Li Z，et al. Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China [J]. Neurol Res，2017，39（6）：492-497.
[23] Shang P，Liu GG，Zheng X，et al. Association Between Medication Adherence and 1-Year Major Cardiovascular Adverse Events After Acute Myocardial Infarction in China [J]. J Am Heart Assoc，2019，8（9）：e011793.
[24] 张丽琼，蔡乐.高血压患者服药依从性及其影响因素研究现状[J].中华高血压杂志，2020，28（1）：25-29.
[25] Sabate E. Adherence to long-term therapies：Evidence for action [R]. Publicatons of World Health Organization，2003.
[26] Okura Y，Urban LH，Mahoney DW，et al. Agreement between self-report questionnaires and medical record data was substantial for diabetes，hypertension，myocardial infarction and stroke but not for heart failure [J]. J Clin Epidemiol，2004，57（10）：1096-1103.
京公网安备 11010502046598号